Emalex Biosciences

Chicago, Dec. 7, 2021 – Paragon Biosciences is proud to announce that it has been certified as a Great Place to Work®. This prestigious distinction is entirely survey based on what current employees say about their experience working at Paragon.

“Great Place to Work certification is a testament to the Paragon team who is focused on our mission and supported by our company culture of innovation,” said Paragon Chairman and CEO Jeff Aronin. “Our work to solve some of society’s most challenging problems through biology-based scientific breakthroughs demands that we foster an environment that provides our staff with the resources they need to be successful.”

Great Place to Work is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation.

According to Great Place to Work research, job seekers are 4.5 times more likely to find a great boss at a Certified great workplace. Additionally, employees at Certified workplaces are 93% more likely to look forward to coming to work, and are twice as likely to be paid fairly, earn a fair share of the company’s profits and have a fair chance at promotion.

“Great Place to Work Certification isn’t something that comes easily – it takes ongoing dedication to the employee experience,” said Sarah Lewis-Kulin, vice president of global recognition at Great Place to Work. “It’s the only official recognition determined by employees’ real-time reports of their company culture. Earning this designation means that Paragon Biosciences is one of the best companies to work for in the country.”

###

About Paragon Biosciences
Paragon is a global life science leader that creates, builds and funds innovative biology-based companies in three key areas: cell and gene therapy, adaptive biology and advanced biotechnology. Paragon identifies unmet needs and uses biology to accelerate scientific breakthroughs to solve some of society’s most challenging problems, enabling us to transform the way people live. The company’s current portfolio includes Castle Creek Biosciences, CiRC Biosciences, Emalex Biosciences, Evozyne, Harmony Biosciences, Qlarity Imaging, and a consistent flow of incubating companies created and supported by the replicable Paragon Innovation Capital™ model. Paragon stands at the intersection of human need, life science, and company creation. For more information, please visit https://paragonbiosci.pairsite.com/.

About Great Place to Work Certification™
Great Place to Work® Certification™ is the most definitive “employer-of-choice” recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place to Work-Certified.

About Great Place to Work®
Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees worldwide and used those deep insights to define what makes a great workplace: trust. Their employee survey platform empowers leaders with the feedback, real-time reporting and insights they need to make data-driven people decisions. Everything they do is driven by the mission to build a better world by helping every organization become a great place to work For All™. Learn more at greatplacetowork.com and on LinkedIn, Twitter, Facebook and Instagram.

Media Contacts:

Evelyn M. O’Connor
Paragon Biosciences
312-847-1335
eo@paragonbiosci.pairsite.com

Paragon’s Portfolio Company Emalex Biosciences Announces Positive Topline Results from Phase 2b Clinical Study Evaluating Ecopipam for Pediatric Tourette Syndrome
Outstanding 2021 for Paragon Biosciences and Our Portfolio Companies